18:00:42 EDT Fri 27 Mar 2026
Enter Symbol
or Name
USA
CA



United-Guardian Reports 2025 Financial Results

2026-03-27 09:00 ET - News Release

HAUPPAUGE, N.Y., March 27, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) reported that net sales and net income for FY 2025 decreased compared to FY 2024. Net sales for the year decreased by 13% from $12,181,971 in 2024 to $10,545,468 in 2025, generating net income of $3,250,875 ($0.71 per share) in 2024 compared to $2,105,738 ($0.46 per share) in 2025.

Donna Vigilante, President of United-Guardian, stated, “Our financial performance in 2025 was primarily impacted by the decrease in sales of our cosmetic ingredients. One of the issues we faced was excess inventory held by our largest cosmetic ingredient distributor, Ashland Specialty Ingredients (“ASI”). The inventory overstock led to reduced order quantities from ASI throughout the year. The situation was further impacted by decreased global demand for our products, particularly in China, where heightened competition from local Asian producers, and the impact of global tariffs, negatively impacted sales. In response to these challenges, we have been collaborating closely with our distributor in China to regain lost market share, offering competitive pricing where feasible, differentiating our products from the competition, and exploring new markets where cost pressures are less pronounced.”

“On a positive note, sales of pharmaceuticals and medical lubricants increased in 2025 compared to 2024, by 15% and by 4%, respectively. The increase in medical lubricants was driven by greater demand from two of our large contract manufacturer customers in China. The increase in pharmaceutical sales resulted from an increase in sales to all three of our national drug wholesalers, combined with a decrease in Medicare rebates. In 2025 we initiated a new marketing strategy to expand the domestic sales of Renacidin® by increasing awareness of Renacidin and seeking its inclusion on additional drug formularies. I am happy to report that we recently received approval from two major pharmacy benefit managers. We believe that having Renacidin available on additional drug formularies will enhance patient access and will support the product’s long-term commercial growth. We are optimistic that this initiative, along with the new marketing and distribution agreements we entered into in 2025 for our cosmetic ingredients, will result in increased sales in the coming years.”

United-Guardian is a manufacturer of cosmetic ingredients, sexual wellness ingredients, pharmaceuticals, and medical lubricants.

Contact:Donna Vigilante
 (631) 273-0900
 dvigilante@u-g.com


NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.

FINANCIAL RESULTS AS OF AND FOR THE YEARS ENDED

DECEMBER 31, 2025 AND 2024

STATEMENTS OF INCOME
 
  Years ended December 31, 
  2025  2024 
         
Net sales $10,545,468  $12,181,971 
         
Costs and expenses:        
Cost of sales  5,404,328   5,721,584 
Operating expenses  2,434,148   2,356,819 
Research and development  463,644   456,779 
Total costs and expenses  8,302,120   8,535,182 
Income from operations  2,243,348   3,646,789 
Other income:        
Investment income  365,308   434,679 
Net gain on marketable securities  34,359   26,989 
Total other income  399,667   461,668 
         
Income before provision for income taxes  2,643,015   4,108,457 
         
Provision for income taxes  537,277   857,582 
Net income $2,105,738  $3,250,875 
         
Earnings per common share (basic and diluted) $0.46  $0.71 
         
Weighted average shares (basic and diluted)  4,594,319   4,594,319 
         


BALANCE SHEET DATA
(condensed)

 
  December 31, 
  2025  2024 
       
Current assets:$12,201,397 $12,665,551 
Deferred tax asset, net ---  175,397 
Property, plant, and equipment, net 907,182  956,387 
Total assets 13,108,579  13,797,335 
       
Current liabilities: 1,669,321  1,914,469 
Deferred tax liability, net 207,246  --- 
Total liabilities 1,876,567  1,914,469 
       
Stockholders’ equity 11,232,012  11,882,866 
Total liabilities and stockholders’ equity
$
13,108,579 
$
13,797,335 



Primary Logo

© 2026 Canjex Publishing Ltd. All rights reserved.